Two-dose, lipid nanoparticle RNA vaccine

Development status

  1. First COVID-19 vaccine approved worldwide
  2. First-in-class lipid nanoparticle vaccine
  3. Emergency use/conditional marketing authorizations granted in multiple countries
  4. Phase 1 clinical trial (sublicensed to Shanghai Fosun Pharmaceutical [Group] Co Ltd) underway in Mainland China
  5. Phase 3 clinical trials underway in Argentina, Brazil, South Africa and Turkey
  6. Japan PMDA reviewing an application for emergency use
18 active deals

Emergency use
authorizations granted in:

Drugs to Watch - Tozinarmeran Placeholder
Drugs to Watch - Tozinarmeran


The vaccine is well-tolerated, is easily administered.

It has a reported 95% efficacy when administered per protocol, but it requires ultra-cold chain storage.

Drugs to Watch 2021

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team